Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastrooesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial

被引：10

作者：

Zhang, X. ^{[1
]}

Li, Z. ^{[2
]}

Liang, H. ^{[3
]}

Xue, Y. ^{[4
]}

Wang, Y. ^{[5
]}

Zhou, Z. ^{[6
]}

Yu, J. ^{[7
]}

Chen, L. ^{[8
]}

Du, Y. ^{[9
]}

Li, G. ^{[10
]}

Xiao, G. ^{[11
]}

Wu, D. ^{[12
]}

Zhou, Y. ^{[13
]}

Dang, C. ^{[14
]}

He, Y. ^{[15
]}

Zhang, Z. ^{[16
]}

Sun, Y. ^{[17
]}

Li, Y. ^{[18
]}

Shen, L. ^{[1
]}

Ji, J. ^{[2
]}

机构：

[1] Peking Univ Canc Hosp, Dept Gastrointestinal Oncol, Beijing Canc Hosp, Beijing, Peoples R China

[2] Peking Univ Canc Hosp, Gastrointestinal Canc Ctr, Beijing Canc Hosp, Beijing, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Dept Surg, Tianjin, Peoples R China

[4] Harbin Med Univ, Dept Surg, Canc Hosp, Harbin, Peoples R China

[5] Fudan Univ, Dept Surg, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] Sun Yat Sen Univ, Dept Surg, Canc Ctr, Guangzhou, Peoples R China

[7] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Sch Med, Hangzhou, Peoples R China

[8] Chinese Peoples Liberat Army Gen Hosp, Dept Surg, Mil Hosp 301, Beijing, Peoples R China

[9] Zhejiang Canc Hosp, Dept Surg, Hangzhou, Peoples R China

[10] East Theater Gen Hosp PLA, Dept Surg, Nanjing, Peoples R China

[11] Beijing Hosp, Dept Surg, Beijing, Peoples R China

[12] Zhejiang Univ, Dept Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China

[13] Qingdao Univ, Dept Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China

[14] Xi An Jiao Tong Univ, Dept Surg, Affiliated Hosp 1, Xian, Peoples R China

[15] Sun Yat Sen Univ, Dept Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China

[16] Capital Med Univ, Beijing Friendship Hosp, Dept Surg, Beijing, Peoples R China

[17] Fudan Univ, Dept Surg, Zhongshan Hosp, Shanghai, Peoples R China

[18] Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA78

引用

页码：S1318 / S1319

页数：2

共 50 条

[31] Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Shin, Kabsoo
Park, Se Jun
Lee, Jinsoo
Park, Cho Hyun
Song, Kyo Young
Lee, Han Hong
Seo, Ho Seok
Jung, Yoon Ju
Park, Jae Myung
Lee, Sung Hak
Roh, Sang Young
Kim, In-Ho
BMC CANCER, 2019, 19 (01)
[32] Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Kabsoo Shin
Se Jun Park
Jinsoo Lee
Cho Hyun Park
Kyo Young Song
Han Hong Lee
Ho Seok Seo
Yoon Ju Jung
Jae Myung Park
Sung Hak Lee
Sang Young Roh
In-Ho Kim
BMC Cancer, 19
[33] Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Lee, S.
Kim, I-H.
Shin, K.
ANNALS OF ONCOLOGY, 2019, 30
[34] Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial
Xue, Kan
Ying, Xiangji
Bu, Zhaode
Wu, Aiwen
Li, Zhongwu
Tang, Lei
Zhang, Lianhai
Zhang, Yan
Li, Ziyu
Ji, Jiafu
CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (05) : 516 - +
[35] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study.
Zhang, Wen
Du, Chun-Xia
Jiang, Zhichao
Sun, Yongkun
Xie, Yibin
Zhong, Yuxin
Zhu, Yuelu
Jiang, Liming
Dou, Lizhou
Xue, Qi
Shao, Kang
Gao, Shugeng
Wang, Chengfeng
Zhao, Dongbing
Tian, Yantao
Zhou, Ai-Ping
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[36] The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study
Xi Cheng
Shan Yu
Yan Wang
Yuehong Cui
Wei Li
Yiyi Yu
Cheng Tang
Huiqin Jiang
Yuan Ji
Yihong Sun
Xuefei Wang
Zhenbin Shen
Fenglin Liu
Tian-shu Liu
Gastric Cancer, 2019, 22 : 587 - 597
[37] The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study
Cheng, Xi
Yu, Shan
Wang, Yan
Cui, Yuehong
Li, Wei
Tang, Cheng
Jiang, Huiqin
Ji, Yuan
Sun, Yihong
Wang, Xuefei
Shen, Zhenbin
Liu, Fenglin
Liu, Tian-shu
GASTRIC CANCER, 2019, 22 (03) : 587 - 597
[38] A single arm, open-label, multicenter, phase II trial of oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC)
Liu, T.
Yu, Y.
Sun, Y.
Yan, M.
Cao, H.
Liu, Y.
Wang, X.
Shen, Z.
Liu, F.
Wang, Y.
Feng, Y.
ANNALS OF ONCOLOGY, 2015, 26 : 68 - 68
[39] Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched comparison.
Yen, Chih Chieh
Chen, I. Shu
Chao, Ying Jui
Bai, Li-Yuan
Hsu, Chia Yuan
Su, Ping Jui
Liao, Ting Kai
Huang, Chien-Jui
Liu, I. Ting
Shan, Yan Shen
Yen, Chia Jui
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 396 - 396
[40] Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
Yan Wang
Xi Cheng
Yue-hong Cui
Jun Hou
Yuan Ji
Yi-hong Sun
Zhen-bin Shen
Feng-lin Liu
Tian-shu Liu
BMC Cancer, 18

← 1 2 3 4 5 →